-
The role of Epstein-Barr virus in lymphomas of HIV-carriers.
APMIS Suppl. 1989;8:58-61
PMID: 2544216
-
Low HLA-C expression at cell surfaces correlates with increased turnover of heavy chain mRNA.
J Exp Med. 1995 Jun 1;181(6):2085-95
PMID: 7760000
-
An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3).
J Exp Med. 1990 Jan 1;171(1):345-9
PMID: 1688611
-
An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants.
J Virol. 1990 Aug;64(8):3974-6
PMID: 1695259
-
Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity.
J Virol. 1991 Feb;65(2):996-1001
PMID: 1846213
-
Severe chronic active Epstein-Barr virus infection syndrome.
Clin Microbiol Rev. 1991 Jan;4(1):129-35
PMID: 1848476
-
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules.
Nature. 1991 May 23;351(6324):290-6
PMID: 1709722
-
Human T-cell recognition of Epstein-Barr virus-induced replication antigen complexes.
Int J Cancer. 1991 Nov 11;49(5):656-60
PMID: 1657795
-
Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.
J Virol. 1992 Jan;66(1):122-31
PMID: 1309242
-
The specificity of recognition of a cytotoxic T lymphocyte epitope.
Eur J Immunol. 1992 Jan;22(1):191-5
PMID: 1370414
-
Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
J Exp Med. 1992 Jul 1;176(1):169-76
PMID: 1377222
-
Immune surveillance against Epstein-Barr virus.
Semin Immunol. 1992 Apr;4(2):97-104
PMID: 1377517
-
Cytotoxic T lymphocytes show HLA-C-restricted recognition of EBV-bearing cells and allorecognition of HLA class I molecules presenting self-peptides.
J Immunol. 1992 Oct 1;149(7):2406-14
PMID: 1326579
-
HLA class I nucleotide sequences, 1992.
Immunogenetics. 1993;37(4):239-50
PMID: 8420833
-
Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4.
J Virol. 1993 Mar;67(3):1572-8
PMID: 7679748
-
Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
J Exp Med. 1995 Jun 1;181(6):2221-8
PMID: 7539044
-
Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.
Nature. 1995 Jun 22;375(6533):685-8
PMID: 7540727
-
Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus.
J Virol. 1995 Aug;69(8):4872-9
PMID: 7609055
-
Vaccinia virus serpins B13R and B22R do not inhibit antigen presentation to class I-restricted cytotoxic T lymphocytes.
J Gen Virol. 1995 Sep;76 ( Pt 9):2393-8
PMID: 7561783
-
Immune regulation in Epstein-Barr virus-associated diseases.
Microbiol Rev. 1995 Sep;59(3):387-405
PMID: 7565411
-
A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro.
J Virol. 1996 Apr;70(4):2394-402
PMID: 8642667
-
Epstein-Barr virus and the B cell: that's all it takes.
Trends Microbiol. 1996 May;4(5):204-8
PMID: 8727601
-
Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism.
Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9194-9
PMID: 8799177
-
Identification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus.
J Virol. 1996 Dec;70(12):8858-64
PMID: 8971014
-
Lytic replication of Epstein-Barr virus in the peripheral blood: analysis of viral gene expression in B lymphocytes during infectious mononucleosis and in the normal carrier state.
Blood. 1997 Mar 1;89(5):1665-77
PMID: 9057649
-
Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
J Immunol. 1997 Apr 1;158(7):3325-34
PMID: 9120290
-
Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response.
J Exp Med. 1997 May 5;185(9):1605-17
PMID: 9151898
-
Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders.
J Clin Microbiol. 1997 Jun;35(6):1612-5
PMID: 9163497
-
HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population.
Science. 1993 Apr 2;260(5104):98-100
PMID: 7682013
-
The CD8 coreceptor interaction with the alpha 3 domain of HLA class I is critical to the differentiation of human cytotoxic T-lymphocytes specific for HLA-A2 and HLA-Cw4.
Hum Immunol. 1993 Mar;36(3):149-55
PMID: 8320133
-
Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide.
J Exp Med. 1993 Sep 1;178(3):879-87
PMID: 7688791
-
HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.
J Virol. 1993 Dec;67(12):7428-35
PMID: 7693972
-
HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells.
Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):12000-4
PMID: 8265660
-
Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis.
Cell. 1978 May;14(1):9-20
PMID: 667938
-
In vitro expansion of Epstein-Barr virus-specific HLA-restricted cytotoxic T cells direct from the blood of infectious mononucleosis patients.
Immunology. 1987 Dec;62(4):647-54
PMID: 2828228
-
Allele and locus-specific differences in cell surface expression and the association of HLA class I heavy chain with beta 2-microglobulin: differential effects of inhibition of glycosylation on class I subunit association.
Eur J Immunol. 1988 May;18(5):801-10
PMID: 2967765
-
Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen.
J Exp Med. 1988 Oct 1;168(4):1211-24
PMID: 2459295
-
Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency.
Proc Natl Acad Sci U S A. 1988 Nov;85(22):8693-6
PMID: 2847171
-
Use of synthetic oligopeptides in identification and characterization of immunological functions in the amino acid sequence of the envelope protein of HIV-1.
J Acquir Immune Defic Syndr. 1989;2(1):21-7
PMID: 2537398
-
Allele-specific peptide ligand motifs of HLA-C molecules.
Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):12005-9
PMID: 8265661
-
Different activation of Epstein-Barr virus immediate-early and early genes in Burkitt lymphoma cells and lymphoblastoid cell lines.
J Virol. 1994 Feb;68(2):1200-3
PMID: 8289351
-
Epstein-Barr virus strategy in normal and neoplastic B cells.
Cell. 1994 Jun 17;77(6):791-3
PMID: 8004668
-
Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3.
J Gen Virol. 1994 Sep;75 ( Pt 9):2489-93
PMID: 7521394
-
Peptide motifs of HLA-A3, -A24, and -B7 molecules as determined by pool sequencing.
Immunogenetics. 1994;40(4):306-8
PMID: 7521860
-
Characterization of two Epstein-Barr virus epitopes restricted by HLA-B7.
Eur J Immunol. 1995 Jan;25(1):18-24
PMID: 7531143
-
MHC ligands and peptide motifs: first listing.
Immunogenetics. 1995;41(4):178-228
PMID: 7890324
-
Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia.
N Engl J Med. 1989 Sep 21;321(12):784-9
PMID: 2671734